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Maintaining Aim at a Moving Target
Frank C. Detterbeck, MD
Lung cancer accounts for as many cancer deaths as the next four leading causescombined (breast, prostate, colon, and pancreas).1 Formerly a neglected disease, lung
cancer has become a vibrant area of research. A literature search in Medline for “Lung
Cancer” shows a dramatic increase in the number of publications (Figure 1). It was once
possible to be an expert in lung cancer, but now at best, one can be an expert of a particular
aspect. The rapid pace of new findings makes it difficult to stay abreast of even a highly
focused particular aspect.
The rapid advances and increasing focus on only pieces of the entire disease call for
periodic reassessment of the “big picture.” Lung cancer has become a dynamic and fluid
field, changing right before our eyes. This article examines changes we must keep in mind
to avoid misinterpretation of new knowledge due to inappropriate comparisons.
SOURCES OF CHANGE
Stage Migration
Stage migration occurs when a subgroup of patients is reassigned from a lower stage to a
higher stage; simple mathematics shows that this results in better survival in both stages.2 Several
recent articles have demonstrated a dramatic stage migration from stage III to stage IV non-small
cell lung cancer (NSCLC) in the United States from 2000 to 2010 (Figures 2 and 3).3–5 A sudden
shift in the proportion of stage IV patients with improved survival occurred in the Surveillance,
Epidemiology, and End Results (SEER)5 and the National Cancer Database.3 The California
Cancer Registry demonstrates a similar increase in stage IV and a corresponding decrease in stage
III NSCLC, which matches the number of positron emission tomography (PET) scans performed.4
Furthermore, PET use correlated with better survival for stage III and stage IV patients.4
The proportion of stage I NSCLC, however, has not changed,3,4 and PET is not
associated with improved survival in these patients.4 This is consistent with extensive data
that imaging detects occult distant metastases in only 3 to 5% in clinical stage I6–10 as
opposed to 25 to 30% in patients with clinical stage III NSCLC.6,7 Thus, the impact of
PET is primarily in finding occult distant disease in higher stage patients.
Stage migration is probably also occurring due to better mediastinal staging. Clinical
guidelines call for invasive mediastinal staging in many patients because both computed
tomography (CT) and PET carry high false-positive and false-negative rates for mediastinal
staging.11 There is a growing awareness that the thoroughness of mediastinal staging is of
major importance.12 More thorough mediastinal staging yields better results; videomediasti-
noscopy and transcervical mediastinal lymphadenectomy13,14 are much better than the average
mediastinoscopy a few years ago.15 How thoroughly endobronchial ultrasound (EBUS) will be
performed as it disperses beyond dedicated enthusiasts remains to be seen.
If invasive mediastinal staging is performed more frequently and more thoroughly,
the impact of a positive mediastinal node is probably changing. A small focus of tumor
found during a staging lymphadenectomy may have different clinical implications than a
positive mediastinoscopy as reported 10 years ago. This may significantly affect the
applicability of data from older studies to guide present patient management.
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Cohort Expansion
Cohort expansion refers to the detection of a larger
cohort of patients; however, although all have the same
disease, the method of detection may skew the traditional and
expanded cohorts along a spectrum (i.e., a greater proportion
with slower growing tumors; Figure 4). The expanded group
may have either a better or worse prognosis; the specific
cohort expansion discussed in this study is also known as
length bias—an older term that most people do not intuitively
understand.
CT screening for lung cancer seems to detect a larger
cohort of patients compared with routine medical care,16,17
and these patients have a higher percentage of tumors with
long volume doubling times (VDT; 400 days in 27%
versus 3% and 800 days in 12% versus 1%).18 These
observations suggest that the higher proportion of stage I
cancers and the good survival observed in CT screening
studies are at least partly due to cohort expansion and are
not fully explained by early detection or lead-time bias.
Earlier data from chest x-ray screening studies also de-
tected more lung cancers overall because of more stage I
and the same number of stage IV cancers.19 –21 Nuanced
treatment approaches may be appropriate for patients with
indolent tumors, rather than labeling them all as overdiag-
nosed and unimportant.22
Cohort expansion is likely to be occurring outside of
CT screening programs because of a marked increase in CT
imaging overall (13,000,000 scans per year in 1990 versus
60,000,000 in 2005 in the United States).23 Incidentally—
detected lung cancers are more similar to screen-detected
cases than routine-care-detected cases (i.e., by stage, size,
histologic type, smoking status, and survival).24,25 Japanese
surgical series—where chest x-ray and CT screening have
been fairly common—have found trends to more stage I and
fewer stage III patients, with improved survival for each stage
during the past 15 to 20 years.26–28 In contrast, earlier
European series (spanning 1969–1985, before widespread
availability of CT) found no change in the proportions or the
survival of stage I, II, or III patients.29
The observations are most consistent with cohort ex-
pansion; potential alternative explanations do not fit the
findings. Stage migration would shift the stage proportions
toward more advanced stage patients. Reverse stage migra-
tion (i.e., more stage I and fewer stage III patients) would
decrease the survival for each cohort. Operating more selec-
tively on fewer stage III patients would account for the
changing proportions of stage I, stage II, and stage III surgical
patients but not the survival trends. Better treatment would
result in better outcomes but should not affect the proportions
of each stage. Lead-time bias could also explain some of the
results but not the change in VDT.
FIGURE 1. Increase in medical literature on lung cancer.
Medline search results for articles on lung cancer, limited to
humans and English language.
FIGURE 2. Changing stage distribution among patients with non-small cell lung cancer (NSCLC). A, Proportion of stage IV
among patients with NSCLC in the National Cancer Database by type of institution. Hospital type is defined by the volume of
total cancer cases seen per year and by the presence of a teaching program. Reproduced with permission from J Thorac On-
col.3. B, Stage distribution in the California Cancer Registry and the percent undergoing positron emission tomography (PET)
imaging. Reproduced with permission from Arch Intern Med.4 Hosp, hospital.
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Disease Evolution
The nature of lung cancer has changed significantly,
with less small cell,30 more adenocarcinoma,28,31 women,3
and never smokers.28 More well-differentiated adenocarcino-
mas are seen, especially in women and in never smokers.32
Cancers presenting as ground glass opacities (GGOs) are
increasingly recognized and are more likely to be indolent
(70%, 50%, and 10%, respectively, had a VDT of more than
400 days in pure GGO, semisolid, and solid tumors in CT
screening studies).18
Lung cancer may be a mixture of distinct diseases, and
we may be witnessing the emergence of a new type of lung
cancer. Lung cancer in nonsmokers harbor different changes
in genetic and epigenetic alterations compared with smok-
ers.33–36 Considering only the aggregate of all patients may
mask important observations as demonstrated by the Iressa
Pan-Asia Study (IPASS) study: in the overall cohort, gefitinib
did not affect median progression-free survival (5.7 versus
5.8 months), whereas it was markedly improved in patients
with an epithelial growth factor receptor mutation (9.3 versus
6.1 months, p  0.001) and markedly diminished in those
without (1.5 versus 5.6 months, p  0.001) an epithelial
growth factor receptor mutation.37
Patients with multiple foci of lung cancer are increas-
ingly recognized (usually presenting as pure or mixed GGO
lesions).38,39 Patients with such multifocal lung cancer seem
more likely to develop additional new primary lung cancers
but less likely to develop nodal or distant metastases.39–42
Nevertheless, multifocal lung cancer is a poorly characterized
entity and whether it can explain the observed findings is
unclear.
Data Transition
Small single institution studies are giving way to im-
pressively large cohorts. For example, the 1997 lung cancer
stage classification system was based on 5317 patients ac-
crued over several decades primarily from one institution,
whereas the 2010 revision is based on more than 100,000
patients from 20 countries diagnosed between 1990 and 2000.
The dramatic increase in data allows many details and sub-
groups to be considered. Nevertheless, it is unclear whether
this constitutes an advance involving increased granularity or
an impediment due to loss of traction in increasingly finer
sand. For example, many believe that the new stage classifi-
cation system has solidly established the prognosis of homo-
geneous subgroups of patients. Actually, however, the prog-
nosis is quite variable, dependent on the geographical region
and the type of source database (Figure 5). The criterion for
definition of tumor, node, and metastasis descriptors and
stage groups was consistent differences in prognosis between
distinct groups within geographic regions, database types,
histologic types, etc., not the actual prognosis.43 Furthermore,
the treatment given to these “homogeneous” cohorts was
quite heterogeneous.44 This creates uncertainty about the
applicability of prognostic data from the impressive lung
cancer staging project to an individual patient.
FIGURE 3. Stage shift between 1998 and 2006 in non-
small cell lung cancer (NSCLC). Proportions of patients with
NSCLC by stage in the National Cancer Database in 1998
and 2006. The major change can be explained by stage mi-
gration of a cohort of patients from stage III to stage IV.
Data taken from Morgensztern et al.3
FIGURE 4. Schematic diagram of cohort expansion. An in-
creased prevalence of computed tomography (CT) imaging
can result in more patients with lung cancer with more in-
dolent disease.
FIGURE 5. Variation in prognosis by geographic region and
type of source database. Variations in median survival in the
International Association for the Study of Lung Cancer
(IASLC) database for clinical T categories.43 Note that de-
spite the variations, the T descriptor categories showed con-
sistent differences between one another within each geo-
graphic region or type of source database.
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Increasing data complexity also makes interpretation
more obscure. Complex statistical analyses can make it dif-
ficult to judge whether the analysis makes clinical sense. At
best, increasing statistical complexity makes the conclusions
more difficult to remember (e.g., the new lung cancer stage
classification system) and at worst represents a (statistically
valid) exercise that has lost clinical relevance.
We are also shifting from data collected specifically for
a clinical question (e.g., institutional series or cancer regis-
tries) to data not designed for clinical questions but available
in large quantities (e.g., administrative data). Such data pro-
vide a population-based overview of actual implementa-
tion45,46 but lack sufficient detail to clearly define the cause of
observed results and are, therefore, prone to misinterpreta-
tion. Note that population-based outcome studies assume the
patient population, and treatments are stable with the excep-
tion of the 1 to 2 factors being studied.45 This assumption
must be made with caution, as this article illustrates.
Statistical Sophistication
Many factors are associated with prognosis in addition
to stage (e.g., laboratory tests, performance status, gender,
and histologic subtype). How prognostic factors should be
combined with the tumor, node, and metastasis classification
is being debated. One view is that stage classification is
primarily a nomenclature for tumor extent and not an all-
inclusive system to define prognosis.
Increased sophistication is needed to identify truly valid
prognostic factors. Most studies are “phase I” prognostic
studies in which a cohort of patients is analyzed for multiple
(often empirically chosen) factors. The chance of erroneous
identification of an unsound factor is quite high, and without
independent validation, such factors should be given no
credence. A valid factor must also add additional prognostic
value beyond other factors already widely tested and used.
Furthermore, p values are widely misunderstood and of
questionable applicability to sophisticated analyses of prog-
nostic factors.47,48 The transition to large, nonclinical data-
bases makes it especially important to be sophisticated and
critical in identifying prognostic factors.
Advances in molecular biology have identified lung
cancers in which targeted inhibition of the key driver of cell
growth results in dramatic disease control.49–51 This has led
to the concept that eventually tumors will be characterized by
genetic features instead of anatomic tumor extent (Figure 6).
Nevertheless, studies of genetic prognostic factors to date
have significant limitations,52 and validated factors with util-
ity above that of traditional factors have not been identified
(although some factors predict response to a particular tar-
geted agent).53,54
DISCUSSION—IMPLICATIONS OF CHANGES
The evidence for stage migration and cohort expansion
in lung cancer is strong; this should be considered when
applying earlier clinical trial results to contemporary patients.
For example, if the prognosis of stages I to II NSCLC is
improving, should we be more restrained in using adjuvant
chemotherapy? If more patients with stage IV NSCLC have
limited distant metastatic disease, should we manage them
with curative-intent treatment? Should treatment be less ag-
gressive in patients with indolent tumors? We do not have
robust data addressing these questions, but awareness of
evolving changes is useful in making management decisions
for current patients.
Clinical guidelines, an increasingly common way of
managing the voluminous literature, should also consider
evolving changes (i.e., less heavily weighting earlier studies
or those using outdated staging or selection criteria). Ac-
counting for evolving trends is crucial in designing new
clinical trials; frequently, trials end up underpowered because
the control arm outcome is higher than was anticipated when
the study was designed. The observed changes not only call
into question clinical trials with long accrual times but also
underscore the importance of randomized trials, which ac-
count for both anticipated and unanticipated confounding
factors.
Some of the observed changes do not entirely fit the
interpretations presented in this article. National registry data
showing a stable proportion of stage I NSCLC conflict with
the data supporting cohort expansion. Perhaps, this represents
a balance between cohort expansion (leading to more stage I
patients) and stage migration (leading to fewer stage I pa-
tients).
Large administrative databases generally lack sufficient
detail to answer clinical questions (but may be useful to
assess evolving changes). Increasing data complexity re-
quires clinicians to have a greater knowledge of statistics.
Nevertheless, analyses must be understandable and presented
in a way that can be applied clinically. We must also become
more nuanced in our analyses if lung cancer is a collection of
diseases. More exploratory subgroup analyses are needed but
must be sufficiently validated before they are accepted.
Although genetic characterization of lung cancers holds
great promise, using this to define prognosis above traditional
factors has been elusive so far.52,53 We should remember that
the same enthusiasm existed 15 years ago toward tumor
markers to define prognosis (e.g., Kras and p53)55,56 but
without the anticipated success.57 The potential financial
FIGURE 6. Genetic subtyping of non-small cell lung cancer
(NSCLC) and treatment with tailored drugs. Schematic dia-
gram of estimated proportion of identified genetic muta-
tions and potential specific targeted therapies.
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return and ensuing availability of industry funding may create
an excessive focus on drug discovery. Other questions may
also have significant therapeutic implications, such as
whether molecular characteristics can predict tumor behavior
(i.e., propensity for local growth, dissemination, or multifocal
involvement).58
There may be similarities between lung and oral cancer,
in which human papillomavirus-related cancers have become
prominent,59,60 with a different anatomic distribution, prog-
nosis, and response to treatment.60 Nevertheless, data linking
HPV and lung cancer61,62 are inconsistent.61,63 Perhaps, this is
because we are looking at lung cancer only as an aggregate.
Finally, as the amount and complexity of data on lung
cancer grow, it is increasingly difficult to provide optimal
care outside of a functional multidisciplinary team, which
must invest time to collaboratively develop an evidence-
based organized approach. This is difficult in the U.S. health
care environment, which fosters fragmentation, individual
viewpoints, and increasingly emphasizes throughput.
CONCLUSION
Stage migration and cohort expansion should be con-
sidered in applying data from past studies to contemporary
patients. We must be nuanced in our analyses, considering
that lung cancer may be a collection of distinct diseases,
while also being more critical and statistically sophisticated.
Large databases provide not only new avenues for insight but
also challenges for correct interpretation. An awareness of
evolving changes in lung cancer is important for the delivery
of optimal clinical care, implementation of clinical trial
results, and in the design of future research studies.
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